Why Are Novavax Shares Trading Higher Today?

Novavax Inc NVAX has completed its rolling submission to Health Canada for the authorization of its protein-based COVID-19 vaccine candidate.
In addition, the Company has completed the submission of all data and modules to the European Medicines Agency (EMA) to support the final regulatory review of its dossier.
The chemistry, manufacturing, and controls (CMC) data packages submitted leverage Novavax's manufacturing partnership with the Serum Institute of India Pvt. Ltd. (SII), the largest supplier of COVID-19 vaccines.
It will later include data from additional manufacturing sites in Novavax's global supply chain.
Related Link: Novavax Rips Higher After Completing Regulatory Filing For Authorization Of COVID-19 Vaccine In UK.
Separately, the regulatory authority of Indonesia has granted emergency use authorization (EUA) for Novavax's COVID-19 vaccine, manufactured by Serum Institute under the brand name COVOVAX.
Novavax and SII have already filed for Novavax's COVID-19 vaccine authorization in India and the Philippines and Emergency Use Listing (EUL) with the World Health Organization (WHO).
The Company will submit its complete package to the FDA by the end of 2021.
Price Action: NVAX shares are up 10.2% at $163.97 during the premarket session on Monday's last check.
Photo by hakan german from Pixabay